<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155778</url>
  </required_header>
  <id_info>
    <org_study_id>HGT-SAN-055</org_study_id>
    <secondary_id>2009-015984-15</secondary_id>
    <nct_id>NCT01155778</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients</brief_title>
  <official_title>A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan N-Sulfatase (rhHNS) Intrathecal Administration Via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sanfilippo syndrome, or Mucopolysaccharidosis (MPS) III, is a rare lysosomal storage disease
      (LSD) caused by loss in activity of 1 of 4 enzymes necessary for degradation of the
      glycosaminoglycan (GAG) heparan sulfate (HS) in lysosomes. MPS IIIA results from deficiency
      of the enzyme heparan N-sulfatase (sulfamidase). MPS IIIA symptoms arise on average at 7
      months of age, with the average age of diagnosis at 4.5 years for the majority of patients.
      The central nervous system (CNS) is the most severely affected organ system in patients with
      MPS IIIA, evidenced by deficits in language development, motor skills, and intellectual
      development. In addition, there are abnormal behaviors including but not limited to
      aggression and excess motor activity/hyperactivity that contribute to disturbances in
      sleep.Overall, individuals with MPS IIIA have a marked developmental delay and significantly
      reduced lifespan of 15 years of age on average.

      The purpose of this study is to determine the safety and tolerability of rhHNS via ascending
      doses administered via an a surgically implanted intrathecal drug delivery device (IDDD)
      intrathecal (IT) route once monthly (or every two weeks) for 6 months in patients with MPS
      IIIA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No effective, disease-modifying therapies are currently approved as treatments for this
      devastating and disabling disease.

      Shire Human Genetic Therapies (Shire HGT) is developing a sulfamidase enzyme replacement
      therapy (ERT)rhHNS for patients with MPS IIIA. recombinant human heparan-N-sulfatase (rhHNS)
      is being administered into the cerebrospinal fluid (CSF) via an surgically implanted
      intrathecal drug delivery device (IDDD), because when administered intravenously (IV) it does
      not cross the blood brain barrier (BBB).

      This study is a multicenter, multiple-dose, dose escalation study designed to evaluate the
      safety, tolerability, and clinical activity of up to 3 dose levels (10mg,45mg and 90mg
      monthly for 6 months) of rhHNS administered via an IDDD in patients with Sanfilippo syndrome
      Type A ages greater than or equal to 3 years of age.

      Patients who have completed all study requirements in this study will be invited to
      participate in an open-label extension study that will be designed to evaluate long term
      safety and clinical outcomes of intrathecal administration of rhHNS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1, 2010</start_date>
  <completion_date type="Actual">September 1, 2012</completion_date>
  <primary_completion_date type="Actual">September 1, 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Emergent Serious Adverse Events (SAE)</measure>
    <time_frame>Baseline to week 30 (follow-up)</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline to week 30 (follow-up)</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Anti-rhHNS Antibody Status in Cerebrospinal Fluid (CSF) by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Participants with positive, negative and missing status were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Anti-rhHNS Antibody Status in Serum by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Participants with positive, negative and missing status were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Intrathecal Drug Device (IDDD) Failures at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Participants with IDDD failures were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Developmental Quotient (DQ) Using Bayley Scales of Infant Development Third Edition (BSID III) and Kaufman Assessment Battery for Children Second Edition (KABC II) at Week 22</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>BSID-III was used to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers. This measure consists of a series of developmental play tasks. Raw scores of successfully completed items are converted to scale scores and to composite scores. The mean composite score is 100 and the standard deviation (SD) is 15.Higher scores are indicative of decreased development. KABC-II was an individually administered measure of the processing and reasoning abilities of children and adolescents between the ages of 3 and 18 years and is an alternative to BSID-III. BSID-III DQ score was based on the Cognitive domain. The DQ score was calculated from the data obtained from either BSID-III/KABC-II mental age equivalent of the child in months divided by the calendar age in months (multiplied by 100 to give percentage points).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Four Point Scoring System/Total Disability Score (FPSS/TDS) at Week 22 and Week 26 (EOS)</measure>
    <time_frame>Baseline, Week 22, Week 26</time_frame>
    <description>FPSS is a sanfilippo-specific disability assessment which assesses motor function, expressive/speech language, and cognitive function on a 0 to 3 point scale. A score of 3 points is assigned for normal function, 2 points for beginning of regression, 1 point for severe level of regression, and 0 points for lost skills. The total disability score (TDS) is the average (0-3) of the motor skills (MS), speech abilities (SA), and cognitive function (CF) scores. Lower scores indicate developmental regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sanfilippo Behavioral Rating Scale (SBRS) at Week 22 and Week 26 (EOS)</measure>
    <time_frame>Baseline, Week 22, Week 26/EOS</time_frame>
    <description>SBRS a parent-scored behavioral inventory measuring: comprehensive language skills, expressive language skills, tantrums, mood and emotions, and other behaviors not otherwise classified. Subscale items are scored 0=Never, 1=Occasionally(5-10%), 2=Sometimes (25%), 3=About half the time, 4=Often(75%), 5=Almost always (90%), 6=Always. Summary scores are the sum of responses within a given domain. Higher values = undesirable behavior. Total score range listed below with the abbreviations. Current Communication (CC)(0-42), Past Communication (PC)(0-42), Orality (0-36), Body Movements (BM)(0-30), Interaction With Objects (IWO)(0-24), Activity And Routines (AAR)(0-36), Emotional Function (EF)(0-18), Safety-consciousness (SC)(0-18), Fearfulness (0-36), Social Interaction (SI)(0-36), Eye Contact (EC)(0-18), Emotional Engagement (EE)(0-18), Comfort Seeking (CS)(0-30), Attention (0-18), Self-control/Compliance (SCC)(0-18), Mood, Anger/Aggression (MAA)(0-42), Self-gratification (SG)(0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Developmental Quotient (DQ) Using Vineland Adaptive Behavioral Scales Second Edition (VABS-II) at Week 22</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>VABS-II measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. It is an instrument that supports the diagnosis of intellectual and developmental disabilities in participants. This test measures 5 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behavior composite (a composite of the other four domains). Scoring is 'Usually' = 2, 'Sometimes'/Partially' = 1 or 'Never' = 0. The raw scores will be converted to domain standard scores (mean 100, SD 15). Higher scores indicate undesirable behavior. The Overall DQ score was calculated from the mean age-equivalent score obtained by averaging out the age equivalent scores for all the sub-domains except for Gross and Fine motor skills.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Movement Assessment Battery for Children Second Edition (MABC-2) at Week 26 (EOS)</measure>
    <time_frame>Baseline, Week 26/EOS</time_frame>
    <description>Movement Assessment Battery for Children, Second Edition (MABC-II) was to be used to identify, describe and guide the treatment of motor impairment in children from 3.0 to 16:11 years of age. As per statistical analysis plan, the outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Parent Form 50 (CHQ-PF50) Questions at Week 22 and Week 26 (EOS)</measure>
    <time_frame>Baseline, Week 22, Week 26/EOS</time_frame>
    <description>CHQ-PF50 which was designed to measure the physical and psychosocial well-being of children 5 years to 18 years of age, consists of 13 health concepts including 11 multi-item and 2 single item scales: Physical Function (PF), Role/Social-Emotional/Behavioral (REB), Role/Social-Physical (RP), bodily pain (BP), General Behavior (BE), Mental Health (MH), Self Esteem (SE), General Health Perceptions (GH), Change in Health (CH), Parental Impact-Emotional (PE), Parental Impact-Time (PT), Family Activities (FA), and Family Cohesion (FC). Transformed scores for all subscales range from 0 to 100, with a higher score indicating better health. Physical and Psychosocial Summary measures (SM) were scored with the use of norm-based methods that standardize the scores to a mean (± Standard Deviation) of 50 ± 10 on the basis of an assessment of the general United States population. Higher values represent better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QoL) Using Infant Toddler Quality of Life Questionnaire™ (ITQOL) at Week 22 and Week 26 (EOS)</measure>
    <time_frame>Baseline, Week 22, Week 26/EOS</time_frame>
    <description>ITQOL is a generic, validated health status measure for children aged 2 months up to 5 years, including items and scales to measure aspects of physical functioning, development, pain, mood, behavior, general health and impact on parents. The ITQOL consists of 97 items that are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health). The score range for all individual subscales is 0 (worst health) to 100 (best health).
Abbreviation: Overall Health (OH), Physical Abilities (PA), Growth And Development (GAD), Bodily Pain (BP), Temperament And Moods (TAM), General Behavior (GEB), Global Behavior (GLB), Getting Along (GA), General Health Perceptions (GHP), PI-Emotion (PIE), PI-Time (PIT), Family Cohesion (FC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Child Form 87 (CHQ-CF87) at Week 26 (EOS)</measure>
    <time_frame>Baseline, Week 26/EOS</time_frame>
    <description>CHQ-CF87 form was designed to be a self-report for participants 10 years and older. It consists of 87 questions and contains the same scales as the PF-50, (with the omission of the parental impact scales and there are no psychosocial and physical summary scores derived). As per statistical analysis plan, the outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QoL) Using Children's Sleep Habits Rating Scale at Week 22 and Week 26 (EOS)</measure>
    <time_frame>Baseline, Week 22, Week 26/EOS</time_frame>
    <description>Children's sleep habits rating scale consisting of 35 item parent questionnaire sleep screening tool. Items are scored on a 3-point scale from 1 (rarely) to 3 (usually) with a Total Sleep Disturbance score (TSDS) ranging from 35-105. Eight subscale scores are totaled to create the TSDS. The subscales are: Bedtime Resistance (BR)(6 items, score = 6-18), Sleep Duration (SD)(3 items, score = 3-9), Parasomnias (P)(7 items, score = 7-21), Sleep Disordered Breathing (SDB)(3 items, score = 3-9), Night Waking (NW)(3 items, score = 3-9), Daytime Sleepiness (DS)(8 items, score = 8-24), Sleep Anxiety (SA)(4 items, score = 4-12), and Sleep Onset Delay (SOD)(1 item, score = 1-3). The questionnaire was designed for children aged 4 through 12 years. A higher score is indicative of more disturbed sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Accumulation of Recombinant Human Heparan N-Sulfatase (rhHNS) in Cerebrospinal Fluid (CSF) at Week 22</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>Cerebrospinal fluid samples were collected from participants through an implanted IDDD or via lumbar puncture (LP) immediately prior to each administration of HGT-1410.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Concentration of Heparan Sulfate and Heparan Sulfate Derivatives in Cerebrospinal Fluid (CSF) at Week 6, 10, 14, 18, 22 and 26(EOS)</measure>
    <time_frame>Baseline, Week 6, 10, 14, 18, 22 and 26(EOS)</time_frame>
    <description>Levels of heparan sulfate and its derivatives were evaluated using the proprietary Sensi-Pro (SP) high-performance liquid chromatography (HPLC) based assay.
Abbreviation: SP Total Heparan Sulfate (SPTHS), SP Non-Reducing End Assay (SPNREA),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brain Magnetic Resonance Imaging (MRI) at Week 22</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>Brain MRI was measured for grey matter volume (GMV) , white matter volume (WMV) and Intracranial cerebrospinal fluid Volume (ICSFV) (Ventricles + Additional CSF Space).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Auditory Brainstem Response (ABR) at Week 22</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Mean ABR air and bone conduction threshold were assessed. Mean ABR bone conduction threshold was not possible to be reported as there was insufficient data to be analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Latencies</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. The Inter-peak Latencies (IPL) were calculated by subtracting the absolute latencies (AL). The Inter-aural Latencies (IAL) were calculated by subtracting the absolute wave V latencies of the right and left ear. IAL, IPL and AL were reported.
Abbreviation: Right Ear (RE), Left Ear (LE), Wave (W), Wave V (WV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitudes</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes by left ear (LE) and right ear (RE) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitude Ratio</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes(A), log-transformed amplitudes (LTA), square-root transformed amplitudes (STA) by left ear (LE) and right ear (RE) wave V/I in ratio was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Latencies</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed latencies (LTL) by left and right ear were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Amplitude</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed amplitudes (LTA) by left and right ear were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Latencies</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed latency (STL) by left and right ear were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Amplitude</measure>
    <time_frame>Baseline, Week 22</time_frame>
    <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed amplitude (STA) by left and right ear were reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Mucopolysaccharidosis (MPS)</condition>
  <arm_group>
    <arm_group_label>10 mg rhHNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mg rhHNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mg rhHNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given IDDD as a 45 mg dose every 14 [±2 days] for a monthly total of 90 mg for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant human heparan N-sulfatase (rhHNS)</intervention_name>
    <arm_group_label>10 mg rhHNS</arm_group_label>
    <arm_group_label>45 mg rhHNS</arm_group_label>
    <arm_group_label>90 mg rhHNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Each patient had to meet the following criteria to be eligible for the study:

          1. a.) Patients had a documented deficiency in sulfamidase enzyme activity of ≤10% of the
             lower limit of the normal range as measured in fibroblasts or leukocytes.

             AND either b or c b.) Patients had a normal enzyme activity level of at least 1 other
             sulfatase (to rule out multiple sulfatase deficiency) as measured in fibroblasts or
             leukocytes.

             c.) Patients had 2 documented mutations.

          2. The patient was ≥3 years of age and had a developmental age ≥1 year.

          3. Patients must have been medically stable, in the opinion of the Investigator, to
             accommodate the protocol requirements, including travel, assessments, and IDDD
             surgery, without placing an undue burden on the patient/patient's family.

          4. The patient's parent(s) or legal guardian must have voluntarily signed an
             Institutional Review Board/Independent Ethics Committee-approved informed consent form
             after all relevant aspects of the study have been explained and discussed with the
             patient, the patient's parent(s), or legal guardian. The patients, patient's parents
             or legal guardian's consent and patient's assent as appropriate, must have been
             obtained.

        Exclusion Criteria

        Patients who met any of the following criteria were excluded from the study:

          1. The patient had significant non-MPS IIIA related CNS impairment or behavioral
             disturbances that would confound the scientific integrity or interpretation of study
             assessments, as determined by the investigator.

          2. The patient had MPS IIIA behavioral-related issues, as determined by the investigator,
             that would have precluded performance of study neurocognitive and developmental
             testing procedures

          3. The patient was pregnant, breast feeding, or was a female patient of childbearing
             potential who would not or could not comply with the use of an acceptable method of
             birth control such as condoms, barrier method, oral contraception, etc.

          4. The patient was blind and/or deaf.

          5. The patient had any known or suspected hypersensitivity to anesthesia or was thought
             to have an unacceptably high risk for anesthesia due to airway compromise or other
             conditions.

          6. The patient or the patient's family had a history of neuroleptic malignant syndrome,
             malignant hyperthermia, or other anesthesia-related concerns.

          7. The investigator may have chosen to exclude patients who have had complications
             resulting from prior lumbar punctures.

          8. The patient had a CNS shunt.

          9. The patient had skeletomuscular/spinal abnormalities or other contraindications for
             the surgical implantation of the IDDD.

         10. The patient had a history of poorly controlled seizure disorder.

         11. The patient was currently receiving psychotropic or other medications, which in the
             investigator's opinion, would have been likely to substantially confound test results
             and the dose and regimen of which cannot be kept constant throughout the study.

         12. The patient could not sustain absence from aspirin, non-steroidal medications, or
             medications that affected blood clotting within 1 week prior to a relevant study
             related procedure (eg, device implantation if applicable), or had ingested such
             medications within 1 week before any procedures in which any change in clotting
             activity would have been deleterious.

         13. The patient had received treatment with any investigational drug or a device intended
             as a treatment for MPS IIIA within the 30 days prior to, or during the study, or was
             enrolled in another study that involved an investigational drug or device (screening
             through safety follow-up contact).

         14. The patient received a hematopoietic stem cell or bone marrow transplant.

         15. The patient's parent(s), or patient's legal guardian(s) was/were unable to provide
             consent or the patient could not provide assent, as appropriate, due to, but not
             limited to, the inability to understand the nature, scope, and possible consequences
             of the study, or did not agree to comply with the protocol defined schedule of
             assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Haslett, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shire Human Genetic Therapies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emma Children's Hospital, Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <results_first_submitted>March 6, 2014</results_first_submitted>
  <results_first_submitted_qc>November 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2018</results_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucopolysaccharidosis (MPS) IIIA</keyword>
  <keyword>Recombinant Human Heparan N-Sulfatase (rhHNS)</keyword>
  <keyword>Sanfilippo Syndrome Type A (MPS IIIA)</keyword>
  <keyword>Lysosomal Storage Disease (LSD)</keyword>
  <keyword>Intrathecal Drug Delivery Device (IDDD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis III</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study enrolled 12 participants and 4 participants were included in each of the 3 dose groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HGT-1410 10 mg</title>
          <description>HGT-1410/rhHNS 10 milligram (mg) monthly via an intrathecal drug delivery device (IDDD) (every 28 [±7 days]) for a total of 6 months.</description>
        </group>
        <group group_id="P2">
          <title>HGT-1410 45 mg</title>
          <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
        </group>
        <group group_id="P3">
          <title>HGT-1410 90 mg</title>
          <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HGT-1410 10 mg</title>
          <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
        </group>
        <group group_id="B2">
          <title>HGT-1410 45 mg</title>
          <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
        </group>
        <group group_id="B3">
          <title>HGT-1410 90 mg</title>
          <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.15" spread="4.7"/>
                    <measurement group_id="B2" value="9.07" spread="9.8"/>
                    <measurement group_id="B3" value="10.64" spread="8.7"/>
                    <measurement group_id="B4" value="9.618" spread="7.2941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Emergent Serious Adverse Events (SAE)</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures.</description>
        <time_frame>Baseline to week 30 (follow-up)</time_frame>
        <population>Safety population was defined as all enrolled participants who received at least 1 dose (full or partial) of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Emergent Serious Adverse Events (SAE)</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures.</description>
          <population>Safety population was defined as all enrolled participants who received at least 1 dose (full or partial) of study drug.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Emergent Adverse Events (TEAE)</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures.</description>
        <time_frame>Baseline to week 30 (follow-up)</time_frame>
        <population>Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Emergent Adverse Events (TEAE)</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAEs) were defined as all adverse events (AEs) from the time of the surgery for IDDD implantation to the last follow up contact, 30 (±7) days after the end of study (EOS) procedures.</description>
          <population>Safety population.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Anti-rhHNS Antibody Status in Cerebrospinal Fluid (CSF) by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group</title>
        <description>Participants with positive, negative and missing status were reported.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent to treat (ITT) population was defined as all enrolled participants who received at least 1 dose (full or partial) of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Anti-rhHNS Antibody Status in Cerebrospinal Fluid (CSF) by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group</title>
          <description>Participants with positive, negative and missing status were reported.</description>
          <population>Intent to treat (ITT) population was defined as all enrolled participants who received at least 1 dose (full or partial) of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Anti-rhHNS Antibody Status in Serum by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group</title>
        <description>Participants with positive, negative and missing status were reported.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Anti-rhHNS Antibody Status in Serum by Recombinant Human Heparan N-Sulfatase (rhHNS) Dose Group</title>
          <description>Participants with positive, negative and missing status were reported.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (Week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Intrathecal Drug Device (IDDD) Failures at Week 26</title>
        <description>Participants with IDDD failures were reported.</description>
        <time_frame>Week 26</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Intrathecal Drug Device (IDDD) Failures at Week 26</title>
          <description>Participants with IDDD failures were reported.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Developmental Quotient (DQ) Using Bayley Scales of Infant Development Third Edition (BSID III) and Kaufman Assessment Battery for Children Second Edition (KABC II) at Week 22</title>
        <description>BSID-III was used to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers. This measure consists of a series of developmental play tasks. Raw scores of successfully completed items are converted to scale scores and to composite scores. The mean composite score is 100 and the standard deviation (SD) is 15.Higher scores are indicative of decreased development. KABC-II was an individually administered measure of the processing and reasoning abilities of children and adolescents between the ages of 3 and 18 years and is an alternative to BSID-III. BSID-III DQ score was based on the Cognitive domain. The DQ score was calculated from the data obtained from either BSID-III/KABC-II mental age equivalent of the child in months divided by the calendar age in months (multiplied by 100 to give percentage points).</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Developmental Quotient (DQ) Using Bayley Scales of Infant Development Third Edition (BSID III) and Kaufman Assessment Battery for Children Second Edition (KABC II) at Week 22</title>
          <description>BSID-III was used to assess the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers. This measure consists of a series of developmental play tasks. Raw scores of successfully completed items are converted to scale scores and to composite scores. The mean composite score is 100 and the standard deviation (SD) is 15.Higher scores are indicative of decreased development. KABC-II was an individually administered measure of the processing and reasoning abilities of children and adolescents between the ages of 3 and 18 years and is an alternative to BSID-III. BSID-III DQ score was based on the Cognitive domain. The DQ score was calculated from the data obtained from either BSID-III/KABC-II mental age equivalent of the child in months divided by the calendar age in months (multiplied by 100 to give percentage points).</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 2, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.91" spread="27.292"/>
                    <measurement group_id="O2" value="43.24" spread="23.112"/>
                    <measurement group_id="O3" value="51.87" spread="36.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 22 (n= 2, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" spread="8.886"/>
                    <measurement group_id="O2" value="-0.89" spread="4.341"/>
                    <measurement group_id="O3" value="-4.91" spread="7.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Four Point Scoring System/Total Disability Score (FPSS/TDS) at Week 22 and Week 26 (EOS)</title>
        <description>FPSS is a sanfilippo-specific disability assessment which assesses motor function, expressive/speech language, and cognitive function on a 0 to 3 point scale. A score of 3 points is assigned for normal function, 2 points for beginning of regression, 1 point for severe level of regression, and 0 points for lost skills. The total disability score (TDS) is the average (0-3) of the motor skills (MS), speech abilities (SA), and cognitive function (CF) scores. Lower scores indicate developmental regression.</description>
        <time_frame>Baseline, Week 22, Week 26</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Four Point Scoring System/Total Disability Score (FPSS/TDS) at Week 22 and Week 26 (EOS)</title>
          <description>FPSS is a sanfilippo-specific disability assessment which assesses motor function, expressive/speech language, and cognitive function on a 0 to 3 point scale. A score of 3 points is assigned for normal function, 2 points for beginning of regression, 1 point for severe level of regression, and 0 points for lost skills. The total disability score (TDS) is the average (0-3) of the motor skills (MS), speech abilities (SA), and cognitive function (CF) scores. Lower scores indicate developmental regression.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MS: Baseline (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.58"/>
                    <measurement group_id="O2" value="3" spread="0"/>
                    <measurement group_id="O3" value="3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS: Change at Week 22 (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MS: Change at Week 26/EOS (n=2,2,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SA: Baseline (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.82"/>
                    <measurement group_id="O2" value="2" spread="0"/>
                    <measurement group_id="O3" value="2" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SA: Change at Week 22 (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.58"/>
                    <measurement group_id="O2" value="0.3" spread="0.58"/>
                    <measurement group_id="O3" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SA: Change at Week 26/EOS (n= 2, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.71"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CF: Baseline (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.5"/>
                    <measurement group_id="O2" value="0.5" spread="0.58"/>
                    <measurement group_id="O3" value="2.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CF: Change at Week 22 (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CF: Change at Week 26/EOS (n= 2, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TDS: Baseline (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="0.569"/>
                    <measurement group_id="O2" value="2.44" spread="0.192"/>
                    <measurement group_id="O3" value="2.58" spread="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TDS: Change at Week 22 (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.319"/>
                    <measurement group_id="O2" value="0.11" spread="0.192"/>
                    <measurement group_id="O3" value="0.08" spread="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TDS: Change at Week 26/EOS (n= 2, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.236"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0.11" spread="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sanfilippo Behavioral Rating Scale (SBRS) at Week 22 and Week 26 (EOS)</title>
        <description>SBRS a parent-scored behavioral inventory measuring: comprehensive language skills, expressive language skills, tantrums, mood and emotions, and other behaviors not otherwise classified. Subscale items are scored 0=Never, 1=Occasionally(5-10%), 2=Sometimes (25%), 3=About half the time, 4=Often(75%), 5=Almost always (90%), 6=Always. Summary scores are the sum of responses within a given domain. Higher values = undesirable behavior. Total score range listed below with the abbreviations. Current Communication (CC)(0-42), Past Communication (PC)(0-42), Orality (0-36), Body Movements (BM)(0-30), Interaction With Objects (IWO)(0-24), Activity And Routines (AAR)(0-36), Emotional Function (EF)(0-18), Safety-consciousness (SC)(0-18), Fearfulness (0-36), Social Interaction (SI)(0-36), Eye Contact (EC)(0-18), Emotional Engagement (EE)(0-18), Comfort Seeking (CS)(0-30), Attention (0-18), Self-control/Compliance (SCC)(0-18), Mood, Anger/Aggression (MAA)(0-42), Self-gratification (SG)(0-24).</description>
        <time_frame>Baseline, Week 22, Week 26/EOS</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sanfilippo Behavioral Rating Scale (SBRS) at Week 22 and Week 26 (EOS)</title>
          <description>SBRS a parent-scored behavioral inventory measuring: comprehensive language skills, expressive language skills, tantrums, mood and emotions, and other behaviors not otherwise classified. Subscale items are scored 0=Never, 1=Occasionally(5-10%), 2=Sometimes (25%), 3=About half the time, 4=Often(75%), 5=Almost always (90%), 6=Always. Summary scores are the sum of responses within a given domain. Higher values = undesirable behavior. Total score range listed below with the abbreviations. Current Communication (CC)(0-42), Past Communication (PC)(0-42), Orality (0-36), Body Movements (BM)(0-30), Interaction With Objects (IWO)(0-24), Activity And Routines (AAR)(0-36), Emotional Function (EF)(0-18), Safety-consciousness (SC)(0-18), Fearfulness (0-36), Social Interaction (SI)(0-36), Eye Contact (EC)(0-18), Emotional Engagement (EE)(0-18), Comfort Seeking (CS)(0-30), Attention (0-18), Self-control/Compliance (SCC)(0-18), Mood, Anger/Aggression (MAA)(0-42), Self-gratification (SG)(0-24).</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CC: Baseline (n= 4, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="5.48"/>
                    <measurement group_id="O2" value="6.3" spread="6.85"/>
                    <measurement group_id="O3" value="10.0" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CC: Change at Week 22 (n= 4, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="13.44"/>
                    <measurement group_id="O2" value="-0.3" spread="1.26"/>
                    <measurement group_id="O3" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CC: Change at Week 26/EOS (n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="12.5"/>
                    <measurement group_id="O2" value="-1.0" spread="1.41"/>
                    <measurement group_id="O3" value="1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC: Baseline (n= 3, 2, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="6.03"/>
                    <measurement group_id="O2" value="8.5" spread="12.02"/>
                    <measurement group_id="O3" value="11.0" spread="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC: Change at Week 22 (n= 1, 0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="NA">Not applicable (NA) signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC: Change at Week 26/EOS (n= 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orality: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="9.9"/>
                    <measurement group_id="O2" value="10.3" spread="2.08"/>
                    <measurement group_id="O3" value="17.3" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orality: Change at Week 22 (n= 2, 3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.83"/>
                    <measurement group_id="O2" value="6.0" spread="5.29"/>
                    <measurement group_id="O3" value="4.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orality: Change at Week 26/EOS (n= 1, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="5" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="4" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BM: Baseline (n= 4, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="4.55"/>
                    <measurement group_id="O2" value="2.5" spread="2.08"/>
                    <measurement group_id="O3" value="12.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BM: Change at Week 22 (n= 3, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.51"/>
                    <measurement group_id="O2" value="2" spread="2.45"/>
                    <measurement group_id="O3" value="-2.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BM: Change at Week 26/EOS (n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.53"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="-2.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IWO: Baseline (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.11"/>
                    <measurement group_id="O2" value="10.3" spread="2.08"/>
                    <measurement group_id="O3" value="8.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IWO: Change at Week 22 (n= 4, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="4.27"/>
                    <measurement group_id="O2" value="-2.0" spread="4.58"/>
                    <measurement group_id="O3" value="-2.0" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IWO: Change at Week 26/EOS (n= 2, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.41"/>
                    <measurement group_id="O2" value="-1.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="-2.0" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AAR: Baseline (n= 1, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="14.3" spread="3.06"/>
                    <measurement group_id="O3" value="12.3" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AAR: Change at Week 22 (n= 1, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="0.7" spread="0.58"/>
                    <measurement group_id="O3" value="-1.3" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AAR: Change at Week 26/EOS (n= 0, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="1.7" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EF: Baseline (n= 3, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.46"/>
                    <measurement group_id="O2" value="2.5" spread="3.11"/>
                    <measurement group_id="O3" value="7.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EF: Change at Week 22 (n= 3, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.46"/>
                    <measurement group_id="O2" value="2.5" spread="3.11"/>
                    <measurement group_id="O3" value="7.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EF: Change at Week 26/EOS (n= 2, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="1.41"/>
                    <measurement group_id="O2" value="0.5" spread="0.71"/>
                    <measurement group_id="O3" value="-1.31" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="5.44"/>
                    <measurement group_id="O2" value="9.5" spread="1.91"/>
                    <measurement group_id="O3" value="11.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.0"/>
                    <measurement group_id="O2" value="1.8" spread="5.74"/>
                    <measurement group_id="O3" value="-0.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC: Change at Week 26/EOS (n= 3, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.65"/>
                    <measurement group_id="O2" value="-3.0" spread="2.83"/>
                    <measurement group_id="O3" value="-1.0" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fearfulness: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="7.81"/>
                    <measurement group_id="O2" value="10.3" spread="8.74"/>
                    <measurement group_id="O3" value="11.0" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fearfulness: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.15"/>
                    <measurement group_id="O2" value="-1.0" spread="5.2"/>
                    <measurement group_id="O3" value="2.0" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fearfulness: Change at Week 26/EOS (n= 2, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.12"/>
                    <measurement group_id="O2" value="-5" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="2.3" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SI: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="3.37"/>
                    <measurement group_id="O2" value="12.5" spread="2.38"/>
                    <measurement group_id="O3" value="14.5" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SI: Change at Week 22 (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.76"/>
                    <measurement group_id="O2" value="0.3" spread="4.04"/>
                    <measurement group_id="O3" value="-0.5" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SI: Change at Week 26/EOS (n= 3, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="8.0"/>
                    <measurement group_id="O2" value="-3.5" spread="4.95"/>
                    <measurement group_id="O3" value="-0.7" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EC: Baseline (n= 4, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="3.59"/>
                    <measurement group_id="O2" value="5.5" spread="3.7"/>
                    <measurement group_id="O3" value="6.7" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EC: Change at Week 22 (n= 4, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.73"/>
                    <measurement group_id="O2" value="0" spread="3.27"/>
                    <measurement group_id="O3" value="-1.0" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EC: Change at Week 26/EOS (n= 3, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.58"/>
                    <measurement group_id="O2" value="-2.0" spread="2.83"/>
                    <measurement group_id="O3" value="-0.7" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EE: Baseline (n= 2, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="4.95"/>
                    <measurement group_id="O2" value="7.3" spread="1.71"/>
                    <measurement group_id="O3" value="8.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EE: Change at Week 22 (n= 1, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-0.5" spread="1.29"/>
                    <measurement group_id="O3" value="-0.8" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EE: Change at Week 26/EOS (n= 0, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-1.0" spread="1.41"/>
                    <measurement group_id="O3" value="0.7" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: Baseline (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="5.32"/>
                    <measurement group_id="O2" value="10.3" spread="3.06"/>
                    <measurement group_id="O3" value="16.5" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="4.73"/>
                    <measurement group_id="O2" value="-1.7" spread="3.06"/>
                    <measurement group_id="O3" value="-2.3" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS: Change at Week 26/EOS (n= 2, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.41"/>
                    <measurement group_id="O2" value="-1.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="-2.3" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="4.65"/>
                    <measurement group_id="O2" value="8.8" spread="1.26"/>
                    <measurement group_id="O3" value="10.5" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="3.16"/>
                    <measurement group_id="O2" value="2.5" spread="2.38"/>
                    <measurement group_id="O3" value="2.3" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention: Change at Week 26/EOS (n= 2, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.12"/>
                    <measurement group_id="O2" value="0.5" spread="0.71"/>
                    <measurement group_id="O3" value="3.3" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCC: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="4.97"/>
                    <measurement group_id="O2" value="7.3" spread="2.22"/>
                    <measurement group_id="O3" value="10.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCC: Change at Week 22 (n= 3, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="4.51"/>
                    <measurement group_id="O2" value="3.3" spread="3.2"/>
                    <measurement group_id="O3" value="2.0" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCC: Change at Week 26/EOS (n= 3, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="4.04"/>
                    <measurement group_id="O2" value="0.5" spread="0.71"/>
                    <measurement group_id="O3" value="2.7" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAA: Baseline (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="4.11"/>
                    <measurement group_id="O2" value="9.7" spread="3.51"/>
                    <measurement group_id="O3" value="17.3" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAA: Change at Week 22 (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="7.78"/>
                    <measurement group_id="O2" value="3.3" spread="5.13"/>
                    <measurement group_id="O3" value="-0.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAA: Change at Week 26/EOS (n= 3, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.06"/>
                    <measurement group_id="O2" value="4.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="-0.7" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG: Baseline (n= 4, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.0"/>
                    <measurement group_id="O2" value="0.3" spread="0.58"/>
                    <measurement group_id="O3" value="4.5" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG: Change at Week 22 (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.15"/>
                    <measurement group_id="O2" value="2.0" spread="1.0"/>
                    <measurement group_id="O3" value="-1.0" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SG: Change at Week 26/EOS (n= 3, 1, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.58"/>
                    <measurement group_id="O2" value="1.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="1.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Developmental Quotient (DQ) Using Vineland Adaptive Behavioral Scales Second Edition (VABS-II) at Week 22</title>
        <description>VABS-II measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. It is an instrument that supports the diagnosis of intellectual and developmental disabilities in participants. This test measures 5 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behavior composite (a composite of the other four domains). Scoring is 'Usually' = 2, 'Sometimes'/Partially' = 1 or 'Never' = 0. The raw scores will be converted to domain standard scores (mean 100, SD 15). Higher scores indicate undesirable behavior. The Overall DQ score was calculated from the mean age-equivalent score obtained by averaging out the age equivalent scores for all the sub-domains except for Gross and Fine motor skills.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Developmental Quotient (DQ) Using Vineland Adaptive Behavioral Scales Second Edition (VABS-II) at Week 22</title>
          <description>VABS-II measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. It is an instrument that supports the diagnosis of intellectual and developmental disabilities in participants. This test measures 5 key domains: communication, daily living skills, socialization, motor skills, and the adaptive behavior composite (a composite of the other four domains). Scoring is 'Usually' = 2, 'Sometimes'/Partially' = 1 or 'Never' = 0. The raw scores will be converted to domain standard scores (mean 100, SD 15). Higher scores indicate undesirable behavior. The Overall DQ score was calculated from the mean age-equivalent score obtained by averaging out the age equivalent scores for all the sub-domains except for Gross and Fine motor skills.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.78" spread="24.747"/>
                    <measurement group_id="O2" value="47.24" spread="26.612"/>
                    <measurement group_id="O3" value="47.71" spread="33.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.38" spread="12.478"/>
                    <measurement group_id="O2" value="-23.96" spread="10.014"/>
                    <measurement group_id="O3" value="-10.18" spread="13.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Movement Assessment Battery for Children Second Edition (MABC-2) at Week 26 (EOS)</title>
        <description>Movement Assessment Battery for Children, Second Edition (MABC-II) was to be used to identify, describe and guide the treatment of motor impairment in children from 3.0 to 16:11 years of age. As per statistical analysis plan, the outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation.</description>
        <time_frame>Baseline, Week 26/EOS</time_frame>
        <population>This outcome measure was not analyzed as it does not meet the pre-specified SAP criteria (outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation).</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Movement Assessment Battery for Children Second Edition (MABC-2) at Week 26 (EOS)</title>
          <description>Movement Assessment Battery for Children, Second Edition (MABC-II) was to be used to identify, describe and guide the treatment of motor impairment in children from 3.0 to 16:11 years of age. As per statistical analysis plan, the outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation.</description>
          <population>This outcome measure was not analyzed as it does not meet the pre-specified SAP criteria (outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Parent Form 50 (CHQ-PF50) Questions at Week 22 and Week 26 (EOS)</title>
        <description>CHQ-PF50 which was designed to measure the physical and psychosocial well-being of children 5 years to 18 years of age, consists of 13 health concepts including 11 multi-item and 2 single item scales: Physical Function (PF), Role/Social-Emotional/Behavioral (REB), Role/Social-Physical (RP), bodily pain (BP), General Behavior (BE), Mental Health (MH), Self Esteem (SE), General Health Perceptions (GH), Change in Health (CH), Parental Impact-Emotional (PE), Parental Impact-Time (PT), Family Activities (FA), and Family Cohesion (FC). Transformed scores for all subscales range from 0 to 100, with a higher score indicating better health. Physical and Psychosocial Summary measures (SM) were scored with the use of norm-based methods that standardize the scores to a mean (± Standard Deviation) of 50 ± 10 on the basis of an assessment of the general United States population. Higher values represent better health.</description>
        <time_frame>Baseline, Week 22, Week 26/EOS</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Parent Form 50 (CHQ-PF50) Questions at Week 22 and Week 26 (EOS)</title>
          <description>CHQ-PF50 which was designed to measure the physical and psychosocial well-being of children 5 years to 18 years of age, consists of 13 health concepts including 11 multi-item and 2 single item scales: Physical Function (PF), Role/Social-Emotional/Behavioral (REB), Role/Social-Physical (RP), bodily pain (BP), General Behavior (BE), Mental Health (MH), Self Esteem (SE), General Health Perceptions (GH), Change in Health (CH), Parental Impact-Emotional (PE), Parental Impact-Time (PT), Family Activities (FA), and Family Cohesion (FC). Transformed scores for all subscales range from 0 to 100, with a higher score indicating better health. Physical and Psychosocial Summary measures (SM) were scored with the use of norm-based methods that standardize the scores to a mean (± Standard Deviation) of 50 ± 10 on the basis of an assessment of the general United States population. Higher values represent better health.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PF: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="47.14"/>
                    <measurement group_id="O2" value="80.28" spread="35.141"/>
                    <measurement group_id="O3" value="66.67" spread="23.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="51.069"/>
                    <measurement group_id="O2" value="-16.39" spread="23.047"/>
                    <measurement group_id="O3" value="5.56" spread="15.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PF: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-24.44" spread="34.57"/>
                    <measurement group_id="O3" value="-11.11" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RP: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="47.14"/>
                    <measurement group_id="O2" value="50" spread="57.735"/>
                    <measurement group_id="O3" value="66.67" spread="47.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RP: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" spread="11.785"/>
                    <measurement group_id="O2" value="8.33" spread="16.667"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RP: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O3" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="14.14"/>
                    <measurement group_id="O2" value="67.5" spread="29.86"/>
                    <measurement group_id="O3" value="30" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" spread="56.57"/>
                    <measurement group_id="O2" value="7.5" spread="15"/>
                    <measurement group_id="O3" value="45" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="50" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.42" spread="2.946"/>
                    <measurement group_id="O2" value="27.92" spread="21.457"/>
                    <measurement group_id="O3" value="33.33" spread="23.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.75" spread="38.537"/>
                    <measurement group_id="O2" value="-5.21" spread="10.417"/>
                    <measurement group_id="O3" value="11.25" spread="15.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GH: Change at Week 26/EOS(n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REB: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="47.14"/>
                    <measurement group_id="O2" value="41.67" spread="50"/>
                    <measurement group_id="O3" value="50" spread="70.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REB: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.89" spread="86.424"/>
                    <measurement group_id="O2" value="11.11" spread="64.788"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REB: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.22" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BE: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="17.678"/>
                    <measurement group_id="O2" value="61.04" spread="15.296"/>
                    <measurement group_id="O3" value="45.83" spread="11.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BE: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.08" spread="8.839"/>
                    <measurement group_id="O2" value="-2.92" spread="15.716"/>
                    <measurement group_id="O3" value="-2.08" spread="2.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BE: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.83" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-14.37" spread="14.437"/>
                    <measurement group_id="O3" value="-8.33" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="7.07"/>
                    <measurement group_id="O2" value="68.8" spread="10.31"/>
                    <measurement group_id="O3" value="10" spread="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="21.21"/>
                    <measurement group_id="O2" value="-2.5" spread="16.58"/>
                    <measurement group_id="O3" value="17.5" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-5" spread="7.07"/>
                    <measurement group_id="O3" value="5" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SE: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="5.893"/>
                    <measurement group_id="O2" value="61.46" spread="18.122"/>
                    <measurement group_id="O3" value="47.92" spread="14.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SE: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="11.785"/>
                    <measurement group_id="O2" value="-3.13" spread="7.116"/>
                    <measurement group_id="O3" value="-4.17" spread="5.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SE: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="8.33" spread="11.785"/>
                    <measurement group_id="O3" value="-8.33" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PE: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" spread="47.14"/>
                    <measurement group_id="O2" value="27.08" spread="22.948"/>
                    <measurement group_id="O3" value="20.83" spread="17.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PE: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="82.496"/>
                    <measurement group_id="O2" value="-2.08" spread="14.232"/>
                    <measurement group_id="O3" value="4.17" spread="5.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PE: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-4.17" spread="5.893"/>
                    <measurement group_id="O3" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="70.711"/>
                    <measurement group_id="O2" value="33.33" spread="28.689"/>
                    <measurement group_id="O3" value="5.56" spread="7.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11" spread="62.854"/>
                    <measurement group_id="O2" value="-5.56" spread="26.45"/>
                    <measurement group_id="O3" value="16.67" spread="23.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.44" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-5.56" spread="23.57"/>
                    <measurement group_id="O3" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FA: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.25" spread="61.872"/>
                    <measurement group_id="O2" value="42.71" spread="13.767"/>
                    <measurement group_id="O3" value="10.42" spread="14.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FA: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="58.926"/>
                    <measurement group_id="O2" value="-7.29" spread="13.767"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FA: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-6.25" spread="2.946"/>
                    <measurement group_id="O3" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="38.89"/>
                    <measurement group_id="O2" value="72.5" spread="14.43"/>
                    <measurement group_id="O3" value="15.0" spread="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="38.89"/>
                    <measurement group_id="O2" value="-6.3" spread="12.5"/>
                    <measurement group_id="O3" value="15.0" spread="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="30" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM Physical: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.44" spread="23.545"/>
                    <measurement group_id="O2" value="31.62" spread="23.071"/>
                    <measurement group_id="O3" value="31.27" spread="18.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM Physical: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.63" spread="29.276"/>
                    <measurement group_id="O2" value="-1.82" spread="6.112"/>
                    <measurement group_id="O3" value="9.21" spread="5.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM Physical: Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.25" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-4.99" spread="8.195"/>
                    <measurement group_id="O3" value="4.96" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM Psychosocial: Baseline (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.16" spread="14.06"/>
                    <measurement group_id="O2" value="33.8" spread="10.879"/>
                    <measurement group_id="O3" value="17.57" spread="2.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM Psychosocial: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="23.341"/>
                    <measurement group_id="O2" value="-0.26" spread="14.004"/>
                    <measurement group_id="O3" value="2.27" spread="4.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM Psychosocial:Change at Week 26/EOS (n= 1, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                    <measurement group_id="O2" value="-1.58" spread="2.584"/>
                    <measurement group_id="O3" value="-2.29" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life (QoL) Using Infant Toddler Quality of Life Questionnaire™ (ITQOL) at Week 22 and Week 26 (EOS)</title>
        <description>ITQOL is a generic, validated health status measure for children aged 2 months up to 5 years, including items and scales to measure aspects of physical functioning, development, pain, mood, behavior, general health and impact on parents. The ITQOL consists of 97 items that are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health). The score range for all individual subscales is 0 (worst health) to 100 (best health).
Abbreviation: Overall Health (OH), Physical Abilities (PA), Growth And Development (GAD), Bodily Pain (BP), Temperament And Moods (TAM), General Behavior (GEB), Global Behavior (GLB), Getting Along (GA), General Health Perceptions (GHP), PI-Emotion (PIE), PI-Time (PIT), Family Cohesion (FC).</description>
        <time_frame>Baseline, Week 22, Week 26/EOS</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life (QoL) Using Infant Toddler Quality of Life Questionnaire™ (ITQOL) at Week 22 and Week 26 (EOS)</title>
          <description>ITQOL is a generic, validated health status measure for children aged 2 months up to 5 years, including items and scales to measure aspects of physical functioning, development, pain, mood, behavior, general health and impact on parents. The ITQOL consists of 97 items that are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health). The score range for all individual subscales is 0 (worst health) to 100 (best health).
Abbreviation: Overall Health (OH), Physical Abilities (PA), Growth And Development (GAD), Bodily Pain (BP), Temperament And Moods (TAM), General Behavior (GEB), Global Behavior (GLB), Getting Along (GA), General Health Perceptions (GHP), PI-Emotion (PIE), PI-Time (PIT), Family Cohesion (FC).</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OH: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="28.28"/>
                    <measurement group_id="O2" value="56.7" spread="49.07"/>
                    <measurement group_id="O3" value="65" spread="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OH: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="-12.5" spread="17.68"/>
                    <measurement group_id="O3" value="15" spread="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OH: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.35" spread="9.405"/>
                    <measurement group_id="O2" value="75.57" spread="39.496"/>
                    <measurement group_id="O3" value="93.35" spread="4.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="11.738"/>
                    <measurement group_id="O2" value="1.65" spread="11.809"/>
                    <measurement group_id="O3" value="-1.7" spread="2.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GAD: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2" spread="18.102"/>
                    <measurement group_id="O2" value="60.83" spread="25.658"/>
                    <measurement group_id="O3" value="56.8" spread="6.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GAD: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="28.709"/>
                    <measurement group_id="O2" value="-22.5" spread="7.071"/>
                    <measurement group_id="O3" value="18.2" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GAD: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.85" spread="5.869"/>
                    <measurement group_id="O2" value="58.33" spread="36.294"/>
                    <measurement group_id="O3" value="62.5" spread="29.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.2" spread="17.678"/>
                    <measurement group_id="O2" value="25" spread="11.738"/>
                    <measurement group_id="O3" value="12.5" spread="41.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAM: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2" spread="17.678"/>
                    <measurement group_id="O2" value="68.97" spread="21.731"/>
                    <measurement group_id="O3" value="52.8" spread="15.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAM: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.6" spread="21.637"/>
                    <measurement group_id="O2" value="-2.75" spread="33.446"/>
                    <measurement group_id="O3" value="-5.6" spread="19.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAM: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GEB: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.35" spread="32.456"/>
                    <measurement group_id="O2" value="34.73" spread="17.465"/>
                    <measurement group_id="O3" value="12.5" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GEB: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="8.91"/>
                    <measurement group_id="O2" value="7.25" spread="25.102"/>
                    <measurement group_id="O3" value="18.75" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GEB: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLB: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="38.89"/>
                    <measurement group_id="O2" value="40" spread="34.64"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLB: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15" spread="21.21"/>
                    <measurement group_id="O2" value="0" spread="42.43"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLB: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GA: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="17.678"/>
                    <measurement group_id="O2" value="55" spread="15"/>
                    <measurement group_id="O3" value="35.85" spread="1.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GA: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" spread="10.607"/>
                    <measurement group_id="O2" value="-2.5" spread="22.345"/>
                    <measurement group_id="O3" value="-1.65" spread="16.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GA: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GHP: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="4.808"/>
                    <measurement group_id="O2" value="31.8" spread="20.178"/>
                    <measurement group_id="O3" value="57.95" spread="36.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GHP: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" spread="22.486"/>
                    <measurement group_id="O2" value="-5.7" spread="1.556"/>
                    <measurement group_id="O3" value="-3.8" spread="11.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GHP: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIE: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.55" spread="30.335"/>
                    <measurement group_id="O2" value="48.83" spread="33.024"/>
                    <measurement group_id="O3" value="41.65" spread="23.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIE: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.7" spread="25.314"/>
                    <measurement group_id="O2" value="-3.6" spread="25.314"/>
                    <measurement group_id="O3" value="4.75" spread="3.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIE: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIT: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="37.052"/>
                    <measurement group_id="O2" value="49.2" spread="26.264"/>
                    <measurement group_id="O3" value="45.25" spread="63.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIT: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.35" spread="6.718"/>
                    <measurement group_id="O2" value="7.2" spread="23.617"/>
                    <measurement group_id="O3" value="23.8" spread="20.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIT: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC: Baseline (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" spread="0"/>
                    <measurement group_id="O2" value="76.7" spread="14.43"/>
                    <measurement group_id="O3" value="42.5" spread="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC: Change at Week 22 (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="17.68"/>
                    <measurement group_id="O2" value="-12.5" spread="17.68"/>
                    <measurement group_id="O3" value="-27.5" spread="38.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FC: Change at Week 26/EOS (n= 1, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Child Form 87 (CHQ-CF87) at Week 26 (EOS)</title>
        <description>CHQ-CF87 form was designed to be a self-report for participants 10 years and older. It consists of 87 questions and contains the same scales as the PF-50, (with the omission of the parental impact scales and there are no psychosocial and physical summary scores derived). As per statistical analysis plan, the outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation.</description>
        <time_frame>Baseline, Week 26/EOS</time_frame>
        <population>This outcome measure was not analyzed as it does not meet the pre-specified SAP criteria (outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation).</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life (QoL) Using Child Health Questionnaire™ Child Form 87 (CHQ-CF87) at Week 26 (EOS)</title>
          <description>CHQ-CF87 form was designed to be a self-report for participants 10 years and older. It consists of 87 questions and contains the same scales as the PF-50, (with the omission of the parental impact scales and there are no psychosocial and physical summary scores derived). As per statistical analysis plan, the outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation.</description>
          <population>This outcome measure was not analyzed as it does not meet the pre-specified SAP criteria (outcome was to be assessed only if greater than (&gt;) 50 percent (%) of participants were available for the evaluation).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Quality of Life (QoL) Using Children's Sleep Habits Rating Scale at Week 22 and Week 26 (EOS)</title>
        <description>Children's sleep habits rating scale consisting of 35 item parent questionnaire sleep screening tool. Items are scored on a 3-point scale from 1 (rarely) to 3 (usually) with a Total Sleep Disturbance score (TSDS) ranging from 35-105. Eight subscale scores are totaled to create the TSDS. The subscales are: Bedtime Resistance (BR)(6 items, score = 6-18), Sleep Duration (SD)(3 items, score = 3-9), Parasomnias (P)(7 items, score = 7-21), Sleep Disordered Breathing (SDB)(3 items, score = 3-9), Night Waking (NW)(3 items, score = 3-9), Daytime Sleepiness (DS)(8 items, score = 8-24), Sleep Anxiety (SA)(4 items, score = 4-12), and Sleep Onset Delay (SOD)(1 item, score = 1-3). The questionnaire was designed for children aged 4 through 12 years. A higher score is indicative of more disturbed sleep.</description>
        <time_frame>Baseline, Week 22, Week 26/EOS</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quality of Life (QoL) Using Children's Sleep Habits Rating Scale at Week 22 and Week 26 (EOS)</title>
          <description>Children's sleep habits rating scale consisting of 35 item parent questionnaire sleep screening tool. Items are scored on a 3-point scale from 1 (rarely) to 3 (usually) with a Total Sleep Disturbance score (TSDS) ranging from 35-105. Eight subscale scores are totaled to create the TSDS. The subscales are: Bedtime Resistance (BR)(6 items, score = 6-18), Sleep Duration (SD)(3 items, score = 3-9), Parasomnias (P)(7 items, score = 7-21), Sleep Disordered Breathing (SDB)(3 items, score = 3-9), Night Waking (NW)(3 items, score = 3-9), Daytime Sleepiness (DS)(8 items, score = 8-24), Sleep Anxiety (SA)(4 items, score = 4-12), and Sleep Onset Delay (SOD)(1 item, score = 1-3). The questionnaire was designed for children aged 4 through 12 years. A higher score is indicative of more disturbed sleep.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BR: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="1.89"/>
                    <measurement group_id="O2" value="7.3" spread="2.5"/>
                    <measurement group_id="O3" value="11.5" spread="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BR: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.89"/>
                    <measurement group_id="O2" value="1.3" spread="0.96"/>
                    <measurement group_id="O3" value="-0.8" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BR: Change at Week 26/EOS (n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1"/>
                    <measurement group_id="O2" value="1" spread="1.41"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOD: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1"/>
                    <measurement group_id="O2" value="1.8" spread="0.96"/>
                    <measurement group_id="O3" value="2.3" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOD: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.82"/>
                    <measurement group_id="O2" value="0" spread="0.82"/>
                    <measurement group_id="O3" value="0" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOD: Change at Week 26/EOS (n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.58"/>
                    <measurement group_id="O2" value="-0.5" spread="0.71"/>
                    <measurement group_id="O3" value="0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="2.22"/>
                    <measurement group_id="O2" value="6.5" spread="2.65"/>
                    <measurement group_id="O3" value="6" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.99"/>
                    <measurement group_id="O2" value="-0.5" spread="1.29"/>
                    <measurement group_id="O3" value="1.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD: Change at Week 26/EOS (n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.89"/>
                    <measurement group_id="O2" value="-1" spread="1.41"/>
                    <measurement group_id="O3" value="1" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SA: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="1.15"/>
                    <measurement group_id="O2" value="6" spread="1.41"/>
                    <measurement group_id="O3" value="8.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SA: Change at Week 22 (n= 4, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.91"/>
                    <measurement group_id="O2" value="0.8" spread="1.71"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SA: Change at Week 26/EOS (n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.15"/>
                    <measurement group_id="O2" value="0" spread="1.41"/>
                    <measurement group_id="O3" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NW: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.5"/>
                    <measurement group_id="O2" value="5.5" spread="1.91"/>
                    <measurement group_id="O3" value="5.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NW: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.06"/>
                    <measurement group_id="O2" value="0" spread="1.63"/>
                    <measurement group_id="O3" value="-0.5" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NW: Change at Week 26/EOS (n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.73"/>
                    <measurement group_id="O2" value="-0.5" spread="0.71"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P: Baseline (n= 2, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="0.71"/>
                    <measurement group_id="O2" value="10" spread="2.31"/>
                    <measurement group_id="O3" value="12" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P: Change at Week 22 (n= 2, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="0"/>
                    <measurement group_id="O2" value="0.3" spread="3.4"/>
                    <measurement group_id="O3" value="-0.3" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P: Change at Week 26/EOS (n= 1, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="-1" spread="0"/>
                    <measurement group_id="O3" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDB: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.5"/>
                    <measurement group_id="O2" value="4.3" spread="0.5"/>
                    <measurement group_id="O3" value="5.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDB: Change at Week 22 (n= 4, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.96"/>
                    <measurement group_id="O2" value="0.5" spread="1.73"/>
                    <measurement group_id="O3" value="-1.7" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDB: Change at Week 26/EOS(n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.15"/>
                    <measurement group_id="O2" value="-0.5" spread="0.71"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="1.29"/>
                    <measurement group_id="O2" value="11.5" spread="3.87"/>
                    <measurement group_id="O3" value="11.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.5"/>
                    <measurement group_id="O2" value="0.5" spread="0.58"/>
                    <measurement group_id="O3" value="0.5" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DS: Change at Week 26/EOS (n= 3, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.15"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                    <measurement group_id="O3" value="1" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSDS: Baseline (n= 2, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="2.12"/>
                    <measurement group_id="O2" value="50.3" spread="12.28"/>
                    <measurement group_id="O3" value="58.8" spread="16.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSDS: Change at Week 22 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.95"/>
                    <measurement group_id="O2" value="2" spread="5.83"/>
                    <measurement group_id="O3" value="2" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSDS: Change at Week 26/EOS (n= 1, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="-2" spread="4.24"/>
                    <measurement group_id="O3" value="1" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Accumulation of Recombinant Human Heparan N-Sulfatase (rhHNS) in Cerebrospinal Fluid (CSF) at Week 22</title>
        <description>Cerebrospinal fluid samples were collected from participants through an implanted IDDD or via lumbar puncture (LP) immediately prior to each administration of HGT-1410.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Accumulation of Recombinant Human Heparan N-Sulfatase (rhHNS) in Cerebrospinal Fluid (CSF) at Week 22</title>
          <description>Cerebrospinal fluid samples were collected from participants through an implanted IDDD or via lumbar puncture (LP) immediately prior to each administration of HGT-1410.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Concentration of Heparan Sulfate and Heparan Sulfate Derivatives in Cerebrospinal Fluid (CSF) at Week 6, 10, 14, 18, 22 and 26(EOS)</title>
        <description>Levels of heparan sulfate and its derivatives were evaluated using the proprietary Sensi-Pro (SP) high-performance liquid chromatography (HPLC) based assay.
Abbreviation: SP Total Heparan Sulfate (SPTHS), SP Non-Reducing End Assay (SPNREA),</description>
        <time_frame>Baseline, Week 6, 10, 14, 18, 22 and 26(EOS)</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Concentration of Heparan Sulfate and Heparan Sulfate Derivatives in Cerebrospinal Fluid (CSF) at Week 6, 10, 14, 18, 22 and 26(EOS)</title>
          <description>Levels of heparan sulfate and its derivatives were evaluated using the proprietary Sensi-Pro (SP) high-performance liquid chromatography (HPLC) based assay.
Abbreviation: SP Total Heparan Sulfate (SPTHS), SP Non-Reducing End Assay (SPNREA),</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>picomole per milliliter (pmol/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPTHS: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90570.5" spread="38088.67"/>
                    <measurement group_id="O2" value="69049.7" spread="42659.28"/>
                    <measurement group_id="O3" value="83287.0" spread="26012.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPTHS: Change at Week 6 (n= 4, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34167.7" spread="20439.34"/>
                    <measurement group_id="O2" value="-41331.4" spread="38967.66"/>
                    <measurement group_id="O3" value="-65862.6" spread="23010.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPTHS: Week 10 (n= 4, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41825.4" spread="13482.5"/>
                    <measurement group_id="O2" value="-39441.8" spread="29771.14"/>
                    <measurement group_id="O3" value="-54343.7" spread="25891.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPTHS: Change at Week 14 (n= 4, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40309" spread="15107.94"/>
                    <measurement group_id="O2" value="-32249.2" spread="21862.89"/>
                    <measurement group_id="O3" value="-64763.9" spread="25285.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPTHS: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35469.5" spread="20922.54"/>
                    <measurement group_id="O2" value="-44669.5" spread="38360.07"/>
                    <measurement group_id="O3" value="-60931.7" spread="20699.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPNREA: Baseline (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1255.93" spread="471.403"/>
                    <measurement group_id="O2" value="1198.34" spread="627.436"/>
                    <measurement group_id="O3" value="1487.67" spread="329.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPNREA: Change at Week 6 (n= 4, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-213.25" spread="330.836"/>
                    <measurement group_id="O2" value="-677.79" spread="393.281"/>
                    <measurement group_id="O3" value="-1022.53" spread="163.905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPNREA: Change at Week 10 (n= 4, 4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-411.77" spread="268.961"/>
                    <measurement group_id="O2" value="-533.38" spread="476.259"/>
                    <measurement group_id="O3" value="-788.65" spread="390.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPNREA: Change at Week 14 (n= 4, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-359.15" spread="272.695"/>
                    <measurement group_id="O2" value="-491.24" spread="177.701"/>
                    <measurement group_id="O3" value="-1033.58" spread="371.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPNREA: Change at Week 22 (n= 4, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-254.07" spread="333.649"/>
                    <measurement group_id="O2" value="-686.13" spread="517.558"/>
                    <measurement group_id="O3" value="-877.84" spread="435.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brain Magnetic Resonance Imaging (MRI) at Week 22</title>
        <description>Brain MRI was measured for grey matter volume (GMV) , white matter volume (WMV) and Intracranial cerebrospinal fluid Volume (ICSFV) (Ventricles + Additional CSF Space).</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brain Magnetic Resonance Imaging (MRI) at Week 22</title>
          <description>Brain MRI was measured for grey matter volume (GMV) , white matter volume (WMV) and Intracranial cerebrospinal fluid Volume (ICSFV) (Ventricles + Additional CSF Space).</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMV: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.5" spread="111.043"/>
                    <measurement group_id="O2" value="534.25" spread="117.291"/>
                    <measurement group_id="O3" value="600.28" spread="67.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMV: Change at Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.84" spread="36.793"/>
                    <measurement group_id="O2" value="-33.7" spread="24.161"/>
                    <measurement group_id="O3" value="-32.87" spread="36.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WMV: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.72" spread="105.575"/>
                    <measurement group_id="O2" value="348.28" spread="76.854"/>
                    <measurement group_id="O3" value="442.45" spread="79.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WMV: Change at Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" spread="13.997"/>
                    <measurement group_id="O2" value="3.33" spread="11.419"/>
                    <measurement group_id="O3" value="-0.44" spread="9.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICSFV: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.152" spread="9.2975"/>
                    <measurement group_id="O2" value="22.904" spread="20.8459"/>
                    <measurement group_id="O3" value="20.925" spread="15.9681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICSFV: Change at Week 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.739" spread="4.6455"/>
                    <measurement group_id="O2" value="2.886" spread="3.9153"/>
                    <measurement group_id="O3" value="7.375" spread="6.6573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Auditory Brainstem Response (ABR) at Week 22</title>
        <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Mean ABR air and bone conduction threshold were assessed. Mean ABR bone conduction threshold was not possible to be reported as there was insufficient data to be analysed.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Auditory Brainstem Response (ABR) at Week 22</title>
          <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Mean ABR air and bone conduction threshold were assessed. Mean ABR bone conduction threshold was not possible to be reported as there was insufficient data to be analysed.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>Decibel Above Normal Adult Hearing Level</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Ear: Baseline (n= 1, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="56.25" spread="8.839"/>
                    <measurement group_id="O3" value="49.17" spread="14.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ear: Change at Week 22 (n= 1, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O2" value="-3.75" spread="15.91"/>
                    <measurement group_id="O3" value="-0.83" spread="22.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ear: Baseline (n= 2, 2, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="10.607"/>
                    <measurement group_id="O2" value="55.0" spread="7.071"/>
                    <measurement group_id="O3" value="44.38" spread="24.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ear: Change at Week 22 (n= 2, 2, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="7.071"/>
                    <measurement group_id="O2" value="-5.0" spread="14.142"/>
                    <measurement group_id="O3" value="3.13" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Latencies</title>
        <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. The Inter-peak Latencies (IPL) were calculated by subtracting the absolute latencies (AL). The Inter-aural Latencies (IAL) were calculated by subtracting the absolute wave V latencies of the right and left ear. IAL, IPL and AL were reported.
Abbreviation: Right Ear (RE), Left Ear (LE), Wave (W), Wave V (WV)</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Latencies</title>
          <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. The Inter-peak Latencies (IPL) were calculated by subtracting the absolute latencies (AL). The Inter-aural Latencies (IAL) were calculated by subtracting the absolute wave V latencies of the right and left ear. IAL, IPL and AL were reported.
Abbreviation: Right Ear (RE), Left Ear (LE), Wave (W), Wave V (WV)</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>millisecond (ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RE,IPL I-III: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.257"/>
                    <measurement group_id="O2" value="2.53" spread="0.153"/>
                    <measurement group_id="O3" value="2.33" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE,IPL I-III: Change at Week 22 (n= 3, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.147"/>
                    <measurement group_id="O2" value="-0.11" spread="0.183"/>
                    <measurement group_id="O3" value="0.07" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE,IPL III-V: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.24"/>
                    <measurement group_id="O2" value="2.17" spread="0.261"/>
                    <measurement group_id="O3" value="1.96" spread="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE,IPL III-V: Change at Week 22 (n= 3, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.185"/>
                    <measurement group_id="O2" value="-0.06" spread="0.304"/>
                    <measurement group_id="O3" value="0.06" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE,IPL I-V: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="0.047"/>
                    <measurement group_id="O2" value="4.71" spread="0.352"/>
                    <measurement group_id="O3" value="4.29" spread="0.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE,IPL I-V: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.269"/>
                    <measurement group_id="O2" value="-0.17" spread="0.187"/>
                    <measurement group_id="O3" value="0.2" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE,IPL I-III: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.206"/>
                    <measurement group_id="O2" value="2.53" spread="0.153"/>
                    <measurement group_id="O3" value="2.4" spread="0.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE,IPL I-III: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.129"/>
                    <measurement group_id="O2" value="-0.24" spread="0.065"/>
                    <measurement group_id="O3" value="0.11" spread="0.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE,IPL III-V: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="0.255"/>
                    <measurement group_id="O2" value="2.15" spread="0.225"/>
                    <measurement group_id="O3" value="2.09" spread="0.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE,IPL III-V: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.075"/>
                    <measurement group_id="O2" value="0.09" spread="0.091"/>
                    <measurement group_id="O3" value="0.06" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE,IPL I-V: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="0.264"/>
                    <measurement group_id="O2" value="4.68" spread="0.33"/>
                    <measurement group_id="O3" value="4.48" spread="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE,IPL I-V: Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.185"/>
                    <measurement group_id="O2" value="-0.15" spread="0.07"/>
                    <measurement group_id="O3" value="0.17" spread="0.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IAL: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.061"/>
                    <measurement group_id="O2" value="-0.07" spread="0.058"/>
                    <measurement group_id="O3" value="0.07" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IAL: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.301"/>
                    <measurement group_id="O2" value="0.28" spread="0.312"/>
                    <measurement group_id="O3" value="0.46" spread="0.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-RE,WI: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.237"/>
                    <measurement group_id="O2" value="1.59" spread="0.156"/>
                    <measurement group_id="O3" value="1.76" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-RE,WI: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.466"/>
                    <measurement group_id="O2" value="0.46" spread="0.54"/>
                    <measurement group_id="O3" value="0.47" spread="0.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-RE,WIII: Baseline (n= 3, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.45"/>
                    <measurement group_id="O2" value="4.12" spread="0.197"/>
                    <measurement group_id="O3" value="4.09" spread="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-RE,WIII: Change at Week 22 (n= 3, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.355"/>
                    <measurement group_id="O2" value="0.35" spread="0.687"/>
                    <measurement group_id="O3" value="-0.03" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-RE,WV: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" spread="0.283"/>
                    <measurement group_id="O2" value="6.3" spread="0.454"/>
                    <measurement group_id="O3" value="6.06" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-RE,WV: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.478"/>
                    <measurement group_id="O2" value="0.29" spread="0.633"/>
                    <measurement group_id="O3" value="0.67" spread="1.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-LE,WI: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.13"/>
                    <measurement group_id="O2" value="1.68" spread="0.144"/>
                    <measurement group_id="O3" value="1.78" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-LE,WI: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.111"/>
                    <measurement group_id="O2" value="0.16" spread="0.33"/>
                    <measurement group_id="O3" value="0.04" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-LE,WIII: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" spread="0.323"/>
                    <measurement group_id="O2" value="4.22" spread="0.189"/>
                    <measurement group_id="O3" value="4.18" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-LE,WIII: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.165"/>
                    <measurement group_id="O2" value="-0.08" spread="0.266"/>
                    <measurement group_id="O3" value="0.15" spread="0.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-LE,WV: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="0.278"/>
                    <measurement group_id="O2" value="6.36" spread="0.412"/>
                    <measurement group_id="O3" value="6.26" spread="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AL-LE,WV: Change at Week 22 (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.178"/>
                    <measurement group_id="O2" value="0.01" spread="0.324"/>
                    <measurement group_id="O3" value="0.24" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitudes</title>
        <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes by left ear (LE) and right ear (RE) were reported.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitudes</title>
          <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes by left ear (LE) and right ear (RE) were reported.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>microvolt (mcV)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RE, Wave I: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.042"/>
                    <measurement group_id="O2" value="0.42" spread="0.118"/>
                    <measurement group_id="O3" value="0.26" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE, Wave I: Change at Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.042"/>
                    <measurement group_id="O2" value="-0.17" spread="0.147"/>
                    <measurement group_id="O3" value="-0.03" spread="0.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE, Wave III: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.156"/>
                    <measurement group_id="O2" value="0.35" spread="0.195"/>
                    <measurement group_id="O3" value="0.24" spread="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE, Wave III: Change at Week 22 (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.099"/>
                    <measurement group_id="O2" value="-0.12" spread="0.117"/>
                    <measurement group_id="O3" value="-0.16" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE, Wave V: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.403"/>
                    <measurement group_id="O2" value="0.47" spread="0.144"/>
                    <measurement group_id="O3" value="0.32" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RE, Wave V: Change at Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.354"/>
                    <measurement group_id="O2" value="-0.09" spread="0.145"/>
                    <measurement group_id="O3" value="-0.14" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE, Wave I: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.028"/>
                    <measurement group_id="O2" value="0.44" spread="0.199"/>
                    <measurement group_id="O3" value="0.26" spread="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE, Wave I: Change at Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.17"/>
                    <measurement group_id="O2" value="0.02" spread="0.221"/>
                    <measurement group_id="O3" value="-0.01" spread="0.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE, Wave III: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.106"/>
                    <measurement group_id="O2" value="0.38" spread="0.194"/>
                    <measurement group_id="O3" value="0.21" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE, Wave III: Change at Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.057"/>
                    <measurement group_id="O2" value="-0.09" spread="0.188"/>
                    <measurement group_id="O3" value="0.02" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE, Wave V: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.269"/>
                    <measurement group_id="O2" value="0.48" spread="0.123"/>
                    <measurement group_id="O3" value="0.29" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LE, Wave V: Change at Week 22 (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.24"/>
                    <measurement group_id="O2" value="-0.02" spread="0.134"/>
                    <measurement group_id="O3" value="-0.01" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitude Ratio</title>
        <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes(A), log-transformed amplitudes (LTA), square-root transformed amplitudes (STA) by left ear (LE) and right ear (RE) wave V/I in ratio was reported.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Amplitude Ratio</title>
          <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR amplitudes(A), log-transformed amplitudes (LTA), square-root transformed amplitudes (STA) by left ear (LE) and right ear (RE) wave V/I in ratio was reported.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A-RE, Wave V/I: Baseline (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.94"/>
                    <measurement group_id="O2" value="1.09" spread="0.057"/>
                    <measurement group_id="O3" value="1.83" spread="0.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A-RE, Wave V/I: Change at Week 22 (n= 2, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.269"/>
                    <measurement group_id="O2" value="0.42" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="-1.48" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A-LE, Wave V/I: Baseline (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.764"/>
                    <measurement group_id="O2" value="1.26" spread="0.014"/>
                    <measurement group_id="O3" value="2.43" spread="2.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A-LE, Wave V/I: Change at Week 22 (n= 2, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.453"/>
                    <measurement group_id="O2" value="0.28" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="-0.15" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-RE, Wave V/I: Baseline (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.146" spread="0.7733"/>
                    <measurement group_id="O2" value="0.086" spread="0.0519"/>
                    <measurement group_id="O3" value="0.589" spread="0.2227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-RE, Wave V/I: Change at Week 22 (n= 2, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.188" spread="0.3011"/>
                    <measurement group_id="O2" value="0.336" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="-3.245" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-LE, Wave V/I: Baseline (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.195" spread="0.6093"/>
                    <measurement group_id="O2" value="0.231" spread="0.0112"/>
                    <measurement group_id="O3" value="0.572" spread="1.1791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-LE, Wave V/I: Change at Week 22 (n= 2, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.188" spread="0.1787"/>
                    <measurement group_id="O2" value="0.202" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="-0.217" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-RE, Wave V/I: Baseline (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.116" spread="0.4212"/>
                    <measurement group_id="O2" value="1.044" spread="0.0271"/>
                    <measurement group_id="O3" value="1.347" spread="0.1496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-RE, Wave V/I: Change at Week 22 (n= 2, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.082" spread="0.1409"/>
                    <measurement group_id="O2" value="0.188" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="-0.996" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-LE, Wave V/I: Baseline (n= 2, 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.128" spread="0.3385"/>
                    <measurement group_id="O2" value="1.122" spread="0.0063"/>
                    <measurement group_id="O3" value="1.449" spread="0.8078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-LE, Wave V/I: Change at Week 22 (n= 2, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.1448"/>
                    <measurement group_id="O2" value="0.119" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                    <measurement group_id="O3" value="-0.09" spread="NA">NA signifies standard deviation not reported as there was only 1 evaluable participant and data was not available for the specific measure.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Latencies</title>
        <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed latencies (LTL) by left and right ear were reported.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Latencies</title>
          <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed latencies (LTL) by left and right ear were reported.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>log transformed (latency [ms])</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LTL-RE, Wave I: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.1326"/>
                    <measurement group_id="O2" value="0.461" spread="0.0956"/>
                    <measurement group_id="O3" value="0.567" spread="0.0066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-RE, Wave I: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.2585"/>
                    <measurement group_id="O2" value="0.242" spread="0.2791"/>
                    <measurement group_id="O3" value="0.179" spread="0.4104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-RE, Wave III: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.387" spread="0.1121"/>
                    <measurement group_id="O2" value="1.416" spread="0.0483"/>
                    <measurement group_id="O3" value="1.409" spread="0.0439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-RE, Wave III: Change at Week 22 (n= 3, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.0882"/>
                    <measurement group_id="O2" value="0.074" spread="0.148"/>
                    <measurement group_id="O3" value="-0.008" spread="0.0108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-RE, Wave V: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.802" spread="0.0461"/>
                    <measurement group_id="O2" value="1.838" spread="0.0731"/>
                    <measurement group_id="O3" value="1.801" spread="0.0374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-RE, Wave V: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.028" spread="0.0794"/>
                    <measurement group_id="O2" value="0.044" spread="0.0963"/>
                    <measurement group_id="O3" value="0.093" spread="0.1529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-LE, Wave I: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.546" spread="0.0769"/>
                    <measurement group_id="O2" value="0.518" spread="0.0838"/>
                    <measurement group_id="O3" value="0.57" spread="0.1268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-LE, Wave I: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.106" spread="0.0653"/>
                    <measurement group_id="O2" value="0.088" spread="0.1812"/>
                    <measurement group_id="O3" value="0.019" spread="0.0927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-LE, Wave III: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.397" spread="0.0804"/>
                    <measurement group_id="O2" value="1.438" spread="0.0455"/>
                    <measurement group_id="O3" value="1.424" spread="0.1213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-LE, Wave III: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.046" spread="0.0394"/>
                    <measurement group_id="O2" value="-0.02" spread="0.0624"/>
                    <measurement group_id="O3" value="0.032" spread="0.0657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-LE, Wave V: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.045"/>
                    <measurement group_id="O2" value="1.849" spread="0.0658"/>
                    <measurement group_id="O3" value="1.831" spread="0.0955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTL-LE, Wave V: Change at Week 22 (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.0281"/>
                    <measurement group_id="O2" value="0.002" spread="0.0494"/>
                    <measurement group_id="O3" value="0.036" spread="0.0338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Amplitude</title>
        <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed amplitudes (LTA) by left and right ear were reported.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Log Transformed Amplitude</title>
          <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR log-transformed amplitudes (LTA) by left and right ear were reported.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>log transformed (amplitude [mcV])</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LTA-RE, Wave I: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.715" spread="0.0867"/>
                    <measurement group_id="O2" value="-0.893" spread="0.2741"/>
                    <measurement group_id="O3" value="-1.379" spread="0.3627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-RE, Wave I: Change at Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.659" spread="0.2456"/>
                    <measurement group_id="O2" value="-0.76" spread="0.8475"/>
                    <measurement group_id="O3" value="-0.24" spread="1.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-RE, Wave III: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.168" spread="0.4901"/>
                    <measurement group_id="O2" value="-1.17" spread="0.6224"/>
                    <measurement group_id="O3" value="-1.527" spread="0.589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-RE, Wave III: Change at Week 22 (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.116" spread="0.2867"/>
                    <measurement group_id="O2" value="-0.549" spread="0.4627"/>
                    <measurement group_id="O3" value="-1.239" spread="1.5038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-RE, Wave V: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.567" spread="0.6834"/>
                    <measurement group_id="O2" value="-0.792" spread="0.2929"/>
                    <measurement group_id="O3" value="-1.19" spread="0.3631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-RE, Wave V: Change at Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.474" spread="0.5435"/>
                    <measurement group_id="O2" value="-0.214" spread="0.3107"/>
                    <measurement group_id="O3" value="-1.237" spread="1.5458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-LE, Wave I: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.918" spread="0.0708"/>
                    <measurement group_id="O2" value="-0.875" spread="0.4212"/>
                    <measurement group_id="O3" value="-1.445" spread="0.5468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-LE, Wave I: Change at Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.409" spread="0.6445"/>
                    <measurement group_id="O2" value="-0.268" spread="0.8163"/>
                    <measurement group_id="O3" value="0.078" spread="0.5695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-LE, Wave III: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.602" spread="0.5149"/>
                    <measurement group_id="O2" value="-1.057" spread="0.4761"/>
                    <measurement group_id="O3" value="-1.643" spread="0.5086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-LE, Wave III: Change at Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.265" spread="0.3271"/>
                    <measurement group_id="O2" value="-0.374" spread="0.7773"/>
                    <measurement group_id="O3" value="0.053" spread="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-LE, Wave V: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.726" spread="0.5418"/>
                    <measurement group_id="O2" value="-0.748" spread="0.2486"/>
                    <measurement group_id="O3" value="-1.372" spread="0.5377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTA-LE, Wave V: Change at Week 22 (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.217" spread="0.4692"/>
                    <measurement group_id="O2" value="-0.066" spread="0.2771"/>
                    <measurement group_id="O3" value="0.006" spread="0.3379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Latencies</title>
        <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed latency (STL) by left and right ear were reported.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population.Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Latencies</title>
          <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed latency (STL) by left and right ear were reported.</description>
          <population>ITT population.Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>square-root transformed (latency [ms])</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STL-RE, Wave I: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.312" spread="0.0886"/>
                    <measurement group_id="O2" value="2.03" spread="0.061"/>
                    <measurement group_id="O3" value="1.328" spread="0.0044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-RE, Wave I: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.1734"/>
                    <measurement group_id="O2" value="0.08" spread="0.1935"/>
                    <measurement group_id="O3" value="0.145" spread="0.3167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-RE, Wave III: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.003" spread="0.1123"/>
                    <measurement group_id="O2" value="2.508" spread="0.0487"/>
                    <measurement group_id="O3" value="2.023" spread="0.0446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-RE, Wave III:Change at Week 22 (n= 3, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" spread="0.0884"/>
                    <measurement group_id="O2" value="0.056" spread="0.1593"/>
                    <measurement group_id="O3" value="-0.008" spread="0.0107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-RE, Wave V: Baseline (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.462" spread="0.0571"/>
                    <measurement group_id="O2" value="1.297" spread="0.091"/>
                    <measurement group_id="O3" value="2.461" spread="0.0461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-RE, Wave V: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" spread="0.0974"/>
                    <measurement group_id="O2" value="0.059" spread="0.1233"/>
                    <measurement group_id="O3" value="0.125" spread="0.2057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-LE, Wave I: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.315" spread="0.05"/>
                    <measurement group_id="O2" value="2.053" spread="0.055"/>
                    <measurement group_id="O3" value="1.332" spread="0.0858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-LE, Wave I: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.068" spread="0.0425"/>
                    <measurement group_id="O2" value="-0.019" spread="0.1223"/>
                    <measurement group_id="O3" value="0.014" spread="0.0608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-LE, Wave III: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.012" spread="0.0805"/>
                    <measurement group_id="O2" value="2.522" spread="0.0464"/>
                    <measurement group_id="O3" value="2.04" spread="0.1236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-LE, Wave III: Change at Week 22 (n= 3, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="0.0403"/>
                    <measurement group_id="O2" value="-0.019" spread="0.0644"/>
                    <measurement group_id="O3" value="0.035" spread="0.0709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-LE, Wave V: Baseline (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.473" spread="0.0559"/>
                    <measurement group_id="O2" value="1.26" spread="0.0824"/>
                    <measurement group_id="O3" value="2.5" spread="0.1208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STL-LE, Wave V: Change at Week 22 (n= 3, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042" spread="0.0354"/>
                    <measurement group_id="O2" value="0.166" spread="0.0633"/>
                    <measurement group_id="O3" value="0.047" spread="0.0438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Amplitude</title>
        <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed amplitude (STA) by left and right ear were reported.</description>
        <time_frame>Baseline, Week 22</time_frame>
        <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>HGT-1410 10 mg</title>
            <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>HGT-1410 45 mg</title>
            <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>HGT-1410 90 mg</title>
            <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Auditory Brainstem Response (ABR) at Week 22: Square-root Transformed Amplitude</title>
          <description>ABR assessments were to be conducted under anesthesia and measured the electrical response evoked by acoustic stimuli as sound is processed along the auditory pathway. Data for change from baseline in ABR square-root transformed amplitude (STA) by left and right ear were reported.</description>
          <population>ITT population. Here, n = participants evaluable for specified category for each arm, respectively.</population>
          <units>square-root transformed(amplitude [mcV])</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STA-RE, Wave I: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.0303"/>
                    <measurement group_id="O2" value="0.644" spread="0.0896"/>
                    <measurement group_id="O3" value="0.507" spread="0.0933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-RE, Wave I: Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.193" spread="0.0535"/>
                    <measurement group_id="O2" value="-0.172" spread="0.1615"/>
                    <measurement group_id="O3" value="-0.044" spread="0.2298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-RE, Wave III: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.566" spread="0.1374"/>
                    <measurement group_id="O2" value="0.575" spread="0.171"/>
                    <measurement group_id="O3" value="0.479" spread="0.1274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-RE, Wave III: Week 22 (n= 2, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038" spread="0.0838"/>
                    <measurement group_id="O2" value="-0.122" spread="0.0927"/>
                    <measurement group_id="O3" value="-0.211" spread="0.2317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-RE, Wave V: Baseline (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.775" spread="0.2599"/>
                    <measurement group_id="O2" value="0.678" spread="0.1022"/>
                    <measurement group_id="O3" value="0.557" spread="0.0954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-RE, Wave V: Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.2183"/>
                    <measurement group_id="O2" value="-0.069" spread="0.1049"/>
                    <measurement group_id="O3" value="-0.197" spread="0.2547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-LE, Wave I: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.632" spread="0.0224"/>
                    <measurement group_id="O2" value="0.655" spread="0.1437"/>
                    <measurement group_id="O3" value="0.499" spread="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-LE, Wave I: Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.101" spread="0.1638"/>
                    <measurement group_id="O2" value="-0.028" spread="0.1961"/>
                    <measurement group_id="O3" value="0.006" spread="0.1365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-LE, Wave III: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.456" spread="0.1162"/>
                    <measurement group_id="O2" value="0.601" spread="0.1508"/>
                    <measurement group_id="O3" value="0.45" spread="0.1131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-LE, Wave III: Week 22 (n= 2, 3, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" spread="0.068"/>
                    <measurement group_id="O2" value="-0.085" spread="0.1798"/>
                    <measurement group_id="O3" value="0.015" spread="0.0422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-LE, Wave V: Baseline (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.709" spread="0.1896"/>
                    <measurement group_id="O2" value="0.692" spread="0.0873"/>
                    <measurement group_id="O3" value="0.518" spread="0.1488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STA-LE, Wave V: Week 22 (n= 2, 3, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.084" spread="0.167"/>
                    <measurement group_id="O2" value="-0.019" spread="0.0956"/>
                    <measurement group_id="O3" value="-0.004" spread="0.0832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 30 (follow-up)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HGT-1410 10 mg</title>
          <description>HGT-1410/rhHNS 10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
        </group>
        <group group_id="E2">
          <title>HGT-1410 45 mg</title>
          <description>HGT-1410/rhHNS 45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months.</description>
        </group>
        <group group_id="E3">
          <title>HGT-1410 90 mg</title>
          <description>HGT-1410/rhHNS 45 mg dose every 14 [±2 days] for a monthly total dose of 90 mg via an IDDD for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Device component issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Implant site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Proteus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>CSF protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>CSF white blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Norovirus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Serum ferritin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="7" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Drooling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="11" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="7" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Labia enlarged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Penile adhesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Infection prophylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Shire’s agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial’s multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Comparison to values obtained in a longitudinal, 12 month, natural history study of untreated participants with MPS IIIA was not reported as it was to be compared with another study protocol HGT-SAN-053 (NCT01047306).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

